Dr. Roskrow is a senior executive with international experience in the healthcare and financial sectors, with a background in hematology and oncology. She has extensive experience from both early and later-stage clinical development of novel anti-cancer compounds, including therapeutic cancer vaccines, and has earned several awards and honors for her research work.

In addition to senior clinical and research positions, Dr. Roskrow has extensive experience as an investment banker, CEO, and Chair, in both private and listed companies, including Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). At present she is Chairman Of The Board ArcticZymes Technologies ASA.

Dr. Roskrow has been involved in executing public and private biotechnology and pharmaceutical merger and acquisition deals, product in/out-licensing deals and financing rounds. Dr. Roskrow has an extensive network of relationships with executives and board members of pharmaceutical and biotechnology companies and leading clinical centers. She holds a BSc (Hons), MBBS (Hons) and a PhD in Immunology, from the University of London.

Dr. Fjällskog is a Senior Life Science Executive with more than 25 years of clinical experience as a medical oncologist within Clinical Research and Development, mainly Immuno-oncology. She is a Board Member of Biovica International AB, Sweden. Previously she has acted as Chief Medical Officer in Sensei Biotherapeutics and Faron Pharmaceuticals Ltd.

Dr. Fjällskog holds a PhD in Oncology and is an Associate Professor (docent) of Oncology affiliated to Uppsala University, Sweden.

Mr. Forbergskog is the CEO of his privately owned investment company, Saturn Invest AS, and serves on the board of several companies. Mr. Forbergskog was the Chief Financial Officer and then Chief Executive Officer of Torghatten ASA. During Forbergskog's tenure at Torghatten ASA, the company grew from being a small locally based provider of transport services, into one of the largest of its kind in the Nordic region, with more than 7,000 employees and an annual turnover of more than NOK 11 billion.

Prior to joining Torghatten ASA, Mr. Forbergskog was an external auditor.

Dr. Hestdal is a Senior Life Science Executive and was previously the Chief Executive Officer of Photocure ASA - a commercial-stage company focused on bladder cancer which is listed on the Oslo Stock Exchange. Currently, Dr. Hestdal is Chief Executive Officer of Caedo Oncology and Serca Pharmaceuticals. He also provides consulting services and expertise related to the development and commercialization of pharma, medtech and biotech companies. 

Dr. Hestdal holds a PhD in immunology.

Dr. Rieger has 15 years experience in cross-functional scientific and business leadership roles spanning business, research operations, drug discovery and product development in the life sciences sector. Dr. Rieger currently serves as Managing Partner at PBM Capital, where he evaluates new investments, closes deals and provides business and technical support to portfolio companies.

Dr. Rieger obtained his PhD from the University of Virginia in Chemistry, has an MBA from the Darden Business School, and earned his B.A. from Rollins College.

Dr. Vågesjö is Co-Founder and Chief Executive Officer of Ilya Pharma AB, a company developing next generation immunotherapies based on cutting edge medical research in immune-physiology and applied microbiology. She has received numerous awards within Science and Innovation, including the Innovators Under 35 Award, Europe division for the MIT Technology Review in 2019. She was also featured on the Global Power List in 2021 by the Medicine Maker. 

Dr. Vågesjö holds a PhD in Physiology from Uppsala University and an MBA from Heriot-Watt University, Edinburgh.